Gastrointestinal Cancer News

An electronic, odor-based tool accurately distinguished pancreatic and ovarian cancer specimens from benign disease and control specimens by analyzing vapors emanating from blood samples, according to results of a small, preliminary study.

Tislelizumab improved overall survival compared with investigator-chosen standard chemotherapy in patients with esophageal squamous cell carcinoma, according to data from a phase 3 study presented at ASCO21.

Black veterans had a higher prevalence of advanced colorectal neoplasia and colorectal cancer compared with white veterans, according to research published in the Journal of Clinical Gastroenterology.

Hepatic arterial infusion chemotherapy of FOLFOX regimens demonstrated superior efficacy and OS than sorafenib as first-line treatment of advanced hepatocellular carcinoma with a heavy intrahepatic tumor burden.

Fecal immunochemical test improved the efficiency of referrals in patients with new-onset lower gastrointestinal symptoms within a primary health care setting, according to research published in Gut.

There are four scenarios in which patients with HCC and extrahepatic disease (EHD) should be considered for locoregional therapy (LRT) in the form of radioembolization or other options (eg, ablation, external radiotherapy).

Liver cancer — the fastest-growing cause of cancer death in the U.S. — has been notoriously difficult to treat.

Adding pembrolizumab to preoperative chemoradiotherapy increased major pathologic response rate compared with historical data among patients with esophageal adenocarcinoma, according to a study presented at the virtual ASCO Annual Meeting.

Liquid biopsy-driven rechallenge with panitumumab led to objective responses in about one-third of patients with metastatic colorectal cancer, according to results of the phase 2 CHRONOS study presented at the virtual ASCO Annual Meeting.

The occurrence of colorectal cancer in colonoscopies performed on patients aged between 45 and 50 years showed rates that approach those in ages 50 to 54 years, according to a presentation at Digestive Diseases Week.